Quantum Genomics announced it is strengthening its leadership team with the appointment of Sarah Merlen-Boulenger as Head of Regulatory Affairs. Sarah Merlen-Boulenger joins Quantum Genomics to lead the preparation of firibastat's registration dossier for the treatment of difficult-to-treat and resistant hypertension, to implement the operational strategy of submitting a New Drug Application (NDA) to the Food Drug Administration (FDA) in the United States, a Marketing Authorization Application to the European Medicines Agency and also to the various health authorities in the territories targeted by Quantum Genomics' pharmaceutical partners. Dr. Boulenger has held various positions in the Regulatory Affairs departments of Sanofi and Ethypharm in France and in the United States.